A key part of Rally’s mission is to find better treatments with fewer long-term side effects, and for almost a decade. Rally has invested...
Research
New and Innovative Study Technique for Osteosarcoma Metastasis
Osteosarcoma (OS) is a type of cancer that begins in the cells that form bones, and mainly affects teenagers and young adults. In...
INSTRuCT Database for Rhabdomyosarcoma Impact
Rally is proud to be the initial funder for the creation of the INSTRuCT Database with a Consortium Grant to Dr. Sam Volchenboum of the...
New RNA Therapies for Glioblastoma from Small Phase 1 Study
Glioblastoma (GBM) in children and adults is a deadly brain tumor with a poor prognosis. Current treatment includes surgery to remove as...
What is Big Data and Childhood Cancer Research
After being born and living in Turkey my whole life, I came to the US for college to study biological sciences at the University of...
AML Treatment Developments
Rally Foundation for Childhood Cancer Research is excited to announce new developments in the treatment of childhood acute myeloid...
The Spark Has Ignited A Fire: How Rally’s Seed Funding Paved the Way for Dr. Volchenboum and the PCDC
At Rally Foundation for Childhood Cancer Research, we often describe ourselves as “philanthropic seed investors in the next great...
Building a Bridge: Expediating and Advancing Pediatric Brain Tumor Research
When to Build a New Bridge I love Rally. I love all the unique opportunities it provides—like building a bridge. Who knew? But first, a...
What is an Astrocytoma?
An astrocytoma is a brain tumor that begins in astrocytes—a type of glial cell that supports nerve cells in the brain. Astrocytomas can be...
The New England Journal of Medicine
Chills ran up and down my arms when I opened the link that Rally-funded researcher Dr. Gregory Friedman sent. I was staring at the New...
Research
Durbin Keeps Asking New Questions
Passion for Pediatric Cancer Patients and Research Drives Meaningful Discovery “Every day, I’m motivated to discover more through research that will enable us to better treat children with cancer and improve outcomes with fewer side effects.” Since his first lab job in the summer between his freshman and sophomore year in college, Adam D. Durbin, MD, PhD, of the Division of Molecular Oncology, Department of Oncology, St. Jude Children’s Research Hospital, has been fascinated by medical...
$56 Million In New Federal Funding
ATLANTA (September 1, 2022) – After six years of intense advocacy with Department of Defense (DOD) Subcommittee members, Rally Foundation for Childhood Cancer Research is excited to announce $56 million in new federal funding this year for cancers affecting children, adolescents, and young adults (AYAs). The $56 million is being awarded from the DOD Congressionally Directed Medical Research Programs’ (CDMRP) Peer Reviewed Cancer Research Program directly to researchers, funding 44 projects....
One Mission, 51 Childhood Cancer Researchers, $3.4 Million in Grants
Rally Foundation for Childhood Cancer Research Awards $3.4 Million in Grants This year, 51 researchers from 31 institutions across the country and worldwide will receive a total of $3.4 million in grants from Rally Foundation for Childhood Cancer Research. “Rally Foundation has now awarded $25.4 million in grants for childhood cancer research since we started in 2005,” says Dean Crowe, Founder and CEO. “From the beginning, our mission has been to fund the best research wherever it may be to...
Pediatric Cancer Dad Discovers a Promising Novel Approach to Wilms’ Tumors
Rally Foundation for Childhood Cancer Research (Rally) likes funding outside-the-box ideas and, at times, funding outside-of-the-box researchers: those who we normally not consider as a scientific researcher. Rally is thrilled to share recent developments from an outside-the-box researcher and his study of Wilms’ Tumor. The study emerges from the Children’s Cancer Therapy Development Institute (cc-TDI) in Beaverton, Oregon, in collaboration with Memorial Sloan Kettering Cancer Center....
What are Oncolytic Viruses?
A key part of Rally’s mission is to find better treatments with fewer long-term side effects, and for almost a decade. Rally has invested for almost a decade in oncolytic virus treatments. A promising, cutting-edge, targeted immunotherapy. Oncolytic viruses are genetically modified viruses or naturally occurring viruses that are reprogrammed to selectively replicate in cancer cells killing the cancer without damaging normal cells. Pretty cool. Josh Bernstock, M.D., Ph.D., shares, “Oncolytic...
New and Innovative Study Technique for Osteosarcoma Metastasis
Osteosarcoma (OS) is a type of cancer that begins in the cells that form bones, and mainly affects teenagers and young adults. In metastatic osteosarcoma, the cancer spreads from the primary bone site to another location, most often the lungs. It can also spread to other bones, the brain or other organs. Currently there are no curative treatments for metastatic osteosarcoma. We urgently need to develop new therapies. To better understand a disease, it is common for tumor research studies to...